The National Institute for Health and Care Excellence (NICE) has recommended cladribine (Mavenclad, Merck Serono) for adults in England with relapsing-remitting multiple sclerosis (RRMS). This decision makes the NHS the first healthcare system in Europe to widely offer the at-home tablet for patients with active MS.
The final draft guidance means cladribine is an option for adults with active RRMS when high-efficacy disease-modifying therapies (DMTs) would be offered.
A Convenient Alternative to Existing Therapies
Cladribine requires just 20 days of dosing over 4 years, offering a more convenient option compared to many existing therapies that require frequent hospital infusions, self-injections, or extensive monitoring.
Patients can avoid lengthy travel to appointments, remain in work, and better plan for starting a…